Automated Insulin Delivery Systems: Today, Tomorrow and User Requirements. (November 2021)

• Record Type: Journal Article
• Authors: Giménez, Marga; Conget, Ignacio; Oliver, Nick
• Is Part Of: Journal of diabetes science and technology. Volume 15:Number 6(2021)
• Page Start: 1252
• Page End: 1257
• Publication Date: 2021-11
• Subjects: type 1 diabetes -- automated insulin delivery -- time in range -- continuous glucose monitoring -- psychosocial aspects; Diabetes -- Periodicals; Medical technology -- Periodicals; Diabetes Mellitus -- Periodicals; 616.462005
• DOI: 10.1177/19322968211029937
• Languages: English
• ISSNs: 1932-2968

Abstract

Automated insulin delivery (AID) is the most recent advance in type 1 diabetes (T1D) management. It has the potential to achieve glycemic targets without disabling hypoglycemia, to improve quality of life and reduce diabetes distress and burden associated with self-management. Several AID systems are currently licensed for use by people with T1D in Europe, United States, and the rest of the world. Despite AID becoming a reality in routine clinical practice over the last few years, the commercially hybrid AID and other systems, are still far from a fully optimized automated diabetes management tool. Implementation of AID systems requires education and support of healthcare professionals taking care of people with T1D, as well as users and their families. There is much to do to increase usability, portability, convenience and to reduce the burden associated with the use of the systems. Co-design, involvement of people with lived experience of T1D and robust qualitative assessment is critical to improving the real-world use of AID systems, especially for those who may have greater need. In addition to this, information regarding the psychosocial impact of the use of AID systems in real life is needed. The first commercially available AID systems are not the end of the development journey but are the first step in learning how to optimally automate insulin delivery in a way that is equitably accessible and effective for people living with T1D.